Financial Survey: Trillium Therapeutics (TRIL) and Sevion Therapeutics (SVON)

Trillium Therapeutics (NASDAQ: TRIL) and Sevion Therapeutics (OTCMKTS:SVON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Trillium Therapeutics and Sevion Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -248.39% -65.21%
Sevion Therapeutics N/A -214.14% -85.35%

Analyst Recommendations

This is a summary of recent ratings for Trillium Therapeutics and Sevion Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 3 0 3.00
Sevion Therapeutics 0 0 0 0 N/A

Trillium Therapeutics presently has a consensus target price of $12.50, suggesting a potential upside of 13.12%. Given Trillium Therapeutics’ higher probable upside, equities analysts clearly believe Trillium Therapeutics is more favorable than Sevion Therapeutics.

Volatility and Risk

Trillium Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Sevion Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Valuation & Earnings

This table compares Trillium Therapeutics and Sevion Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -2.92
Sevion Therapeutics $80,000.00 275.60 -$5.79 million ($0.24) -1.64

Sevion Therapeutics has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Sevion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

47.5% of Trillium Therapeutics shares are owned by institutional investors. 7.7% of Sevion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Sevion Therapeutics Company Profile

Sevion Therapeutics, Inc. is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply